Despite its approval in 1997 by Health Canada, the use of VNS remains limited nationwide. In 2009, the rate of implantation in Canada was 3.5 per million inhabitants compared to 25 per million in the United States (data from Cyberonics). Potential causes include limited funding for VNS devices in Canada, neurologists' misconceptions on VNS efficacy despite published studies, and patients' fear of adverse events. The VNS was first introduced at our center in January 2000. We recently reviewed our experience with vagus nerve stimulation in paediatric epileptic syndromes 7 . The purpose of the present study was to review our experience with VNS in adults with pharmacoresistant epilepsy referred to our tertiary epilepsy center, and to compare our results with those of previous studies.
METHODS
This study included all patients ≥ 16 years old treated for at least 12 months with a VNS for refractory epilepsy, implanted between January 2000 and December 2009 and followed at the Notre-Dame epilepsy clinic. The epilepsy clinic accommodates approximately 600 new patients and 4250 follow-up visits per year, from new onset epilepsy cases to complex drug-refractory patients. Current indications for VNS at our center include a) patients with drug-refractory partial epilepsy not candidate for epilepsy surgery (e.g. multifocal epilepsy, epileptogenic zone overlying eloquent cortex); b) patients who have failed epilepsy surgery; c) patients with cryptogenic or symptomatic generalized epilepsies; d) patients with idiopathic generalized epilepsy who fail to be controlled with appropriate antiepileptic drugs (from lack of efficacy or significant side effects). Patients candidate for a callosotomy were generally offered a VNS first (when available). Choice of treatment for hypothalamic hamartomas (gamma-knife, resection, disconnection, VNS) depended upon its morphological characteristics. Deep brain stimulation is currently not being offered to epileptic patients at our center.
Records (physicians' notes and seizure diaries logged in the patient's file) were reviewed for basic demographic data, results of comprehensive epilepsy evaluations [age of onset, seizure type(s), presumed cause(s)], seizure frequencies at various times pre-and post-implantation, use of AEDs before and after implantation, adverse events related to implantation and stimulation, and use of the magnet. We limited our data collection to up to three years post-implantation. Monthly seizure frequency data was obtained during follow-up visits at 6, 12, 24 and 36 months. Seizure frequency outcome post-VNS was categorized into seven groups: seizure-free, ≥90% seizure reduction, ≥75% seizure reduction, ≥50% seizure reduction, ≥25% seizure reduction, <25% seizure reduction and no seizure reduction or worsening of the epileptic condition. Patients with ≥50% reduction in seizure frequency compared to baseline (i.e. the first four groups) were considered responders to VNS therapy. To compare the number of AEDs before implantation with the last follow-up, a Wilcoxon Signed Rank test was performed.
The VNS therapy system was implanted in each patient by the same neurosurgeon (AB). Initially, the generator was placed in a subcutaneous pocket inferior to the left clavicle. Subsequently, most generators were implanted under the pectoralis muscle for aesthetic reasons. This approach had the additional advantage of preventing the Twiddler's syndrome reported in patients with cardiac pacemakers and deep brain stimulators 8 as well as VNS (personal communication). Stimulation parameters were adjusted according to standard medical practice for VNS-implanted patients 9 . Medications were kept unchanged during the first year of VNS therapy. This study was approved by Notre-Dame Hospital's ethics committee and was not sponsored by the industry.
RESULTS

Baseline data
Between January 2000 and December 2009, a total of 34 epileptic patients (14 male (M), 20 female (F); mean age = 29.9) treated with VNS for at least 12 months were followed at our epilepsy clinic (Table) . Mean age at epilepsy onset and mean duration of epilepsy before implantation were 8.8 years (range 4 months -32 years) and 21.1 years (range 4 -49 years) respectively. Mean age at implantation was 29.9 years (range 16 to 57 years). Most patients had malformations of cortical development (cortical dysplasia, polymicrogyria, heterotopia, tuber, hypothalamic hamartoma, hemimegalencephaly) (n=14; 41%) or atrophy/ gliosis from an acquired insult (meningitis, encephalitis, anoxic-ischemic brain injury) (n = 6; 18%). The majority suffered an epileptic disorder dominated by partial seizures with or without secondary generalization. However, two patients had refractory idiopathic generalized epilepsy. Patients had tried on average 9.6 AEDs (range 5 -17) before receiving VNS therapy, at which point they were taking a mean of 2.9 AEDs (range 1 -5).
VNS parameters
Parameters used in our patient population are shown in Figure 1 . The most frequently employed set of parameters was a current output of 1.50 milliamps (mA) ( Figure 1A ), 'ON' for 30 seconds ( Figure 1B ), 'OFF' for five minutes ( Figure 1C ) for a duty cycle of 10%. For all patients except one, signal frequency was set at 30 hertz (Hz) and pulse width at 500 µ seconds (s). There were no notable differences between maximal and last parameters used. Rapid cycle stimulation was tried on 11 out of 34 patients at some point in the course of their therapy. Magnet "ON" duration was 60 s for all patients and triggered a current intensity that was 0.75 to 1.0 mA greater than the regular current.
Effects of VNS on seizures
Seizure reduction rates available at 6, 12, 24 and 36 months are shown for each patient in the Table. After 6, 12, 24 and 36 months, 14/34 patients (41%), 16/34 patients (47%), 17/30 patients (57%) and 12/20 patients (60%) respectively were responders (Figure 2, 3) . Although some only responded transiently, 16/34 (47%) had a sustained beneficial response for ≥ 1 year during the three year period analyzed in this study. Two patients (6%), #17 with refractory juvenile myoclonic epilepsy and #19 with intractable non-lesional frontal lobe epilepsy, became seizure-free. The effects of VNS did not differ according to seizure type except for two patients: one patient (#4) noted a greater reduction in her occipital lobe complex partial seizures compared to her secondarily generalized tonic-clonic frontal lobe seizures while the other (#32) reported a preferential benefit over her atonic seizures. SC, subcutaneous; SM, submuscular; IGE, idiopathic generalized epilepsy; JME, juvenile myoclonic epilepsy; MTS, mesial temporal sclerosis; CPS, complex partial seizure; SGTC, secondary generalized tonic-clonic seizures; Abs, absence; Myoc, myoclonic seizures; GTC, generalized tonic-clonic seizures; AtyA, atypical absences; Aton, atonic seizures; AEDs, antiepileptic drugs; Multi, multifocal; Temp, temporal lobe; General, generalized; Occipit, occipital lobe; mo, months; yrs, years; L, left; FU, follow-up. Nine patients (26%) felt that use of the magnet had a beneficial effect: 7/9 patients reported that the magnet could abort a seizure if used early enough during the aura while the two remaining patients believed the magnet shortened the ictal and postictal durations. According to patients or caregivers, multiple magnet use was often required to stop a seizure. Three patients reported a decrease of magnet efficacy over time.
Medication modifications following VNS
The mean number of AEDs used by each patient at last follow-up (3.0) was not statistically different from the time of implantation (2.9) (p=0.5605; Wilcoxon Signed Rank test) (Table) . On average, one new AED trial (range 0 -4) was performed after one year of VNS therapy. Only 3/34 patients (9%) had fewer AEDs after VNS therapy, including one patient free of medication at last follow-up. Most patients (24/34; 71%) remained on the same medications and 7/34 patients (21%) had even more AEDs administered daily than previously. In the subgroup of responders at last follow-up, 1/19 (5%) had fewer AEDs after VNS therapy.
Complications related to VNS implantation and stimulationrelated side effects
In terms of surgery-related adverse events, cervical hypoesthesia was reported by eight patients (24%), with partial sensory recovery over the course of months. There were two minor scar infections (one involving the axillar scar and the other over the cervical scar) at 6 and 12 months respectively after VNS implantation. All resolved after antibiotics and did not require device removal. Finally, one patient developed a persistent left Horner syndrome following VNS implantation. Twenty-five patients (74%) had their generator implanted between the chest wall and the pectoralis major muscle compared to nine patients (26%) who had their generator placed subcutaneously. There was no difference in surgery-related complications between both groups. Deeper location of the generator did not affect the ability to interrogate the generator. The most commonly reported side effect from stimulation was voice hoarseness (Figure 4) . Less frequent complaints were coughing, pain (throat, neck, jaw, tooth or headache), cervical paresthesias, dyspnea, and dysphagia. Stimulation-related side effects tended to regress with time. There was no left vocal cord paralysis, lower facial weakness or adverse cardiac events. No dysfunction in the stimulator or in the batteries was noted.
DISCUSSION
Two double-blind, randomized, controlled studies performed in the 1990s have established the efficacy and safety of VNS for the treatment of refractory partial seizures, paving the way for its approval by Health Canada in 1997 4, 5 . Two prospective, longterm, follow-up studies have shown sustained efficacy and tolerability over time 6,10-13 . Improvement is not immediate but tends to increase over 18-24 months of treatment. Despite these studies and several other subsequent positive open-label retrospective studies [14] [15] [16] [17] [18] [19] , use of VNS remains limited in Canada. The implant rate per million inhabitants is 3.5 in Canada compared to 25 in the United States, 16.7 in Norway, 10.7 in Sweden and 7.4 in Great Britain-Ireland (data from Cyberonics). In Quebec, the current implant rate is 4.25 patients per million, i.e. less than 0.5% of the pharmacoresistant epilepsy population. In contrast, approximately 2.5% of pharmacoresistant epilepsy patients in the United States receive VNS therapy (data from Cyberonics).
Possible reasons for underutilization of VNS therapy include Canadian neurologists' misconceptions of its efficacy despite level I and II evidence, patients' ignorance of its existence or fear of adverse events, and lack of funding. Our study, the first reported Canadian series of adult epileptics treated with VNS, demonstrated its efficacy and tolerability in pharmacoresistant epileptics with a responder rate of 41%, 47%, 57% and 60% at 6, 12, 24 and 36 months respectively. This is similar to previous studies that have reported responder rates between 35 and 64% 5, 6, [13] [14] [15] [16] [17] [18] . Furthermore, 6% of our cohort became seizure-free, in line with other studies reporting seizure-free rates ranging from 0 to 8.3% 17, [20] [21] [22] [23] in the adult population and 11-14% 7, 24 in the paediatric population. Despite improvement on seizure frequency, only few patients benefited from medication reduction, as was also noted in our paediatric cohort 7 . On average, one new AED trial was attempted after a year of VNS therapy. This raises the possibility that the higher long-term responder rates reported in VNS studies are partly related to medication changes. This issue is unlikely to be resolved soon as a large randomized controlled study would be costly, possibly unethical, and have high drop out rates. Operative complications were few, consisting mainly of local minor infections and partly expected cervical hypoesthesia. Stimulus-related side effects, mainly coughing, throat pain and hoarseness, tended to improve with time, in concordance with other studies 10 . Implantation of the generator submuscularly instead of subcutaneously did not result in increased difficulty communicating with the device but minimized the risk of Twiddler's syndrome, and was cosmetically more appreciated by patients.
The biggest deterrent to the use of VNS in Canada probably lies in the lack of funding 25 . Because VNS is much more costly than antiepileptic drugs (approximately $23 800 per device), the Health Ministry imposes a quota on epilepsy centers in the province of Quebec and elsewhere. For example, in the greater Montreal area, budget allocation allows implantation of approximately 6 to 10 VNS devices per year for the two paediatric epilepsy centers and 3 to 4 for the two adult epilepsy centers, despite providing tertiary epilepsy care to more than half of the population of the province of Quebec (7,750,504 people). To put things in perspective, more than 2000 cardiac pacemakers and ∼1500 implantable defibrillators are implanted or revised annually in the province without restrictions 26, 27 . These VNS quotas have resulted in significant waiting lists, with the adverse consequence that only the most refractory patients are added to the list (as reflected by the high number of antiepileptic drugs tried by the patients in our study before being implanted). A multicenter study, comparing a group of patients treated with VNS therapy earlier in the course of their epilepsy with a group treated with VNS therapy later in the course, showed that earlier use of VNS therapy significantly improved seizure control. Of the patients in the early group treated within five years after onset or having tried four or fewer antiepileptic drugs, 15% reported no seizures with VNS at three months compared with 4.4% of those in the control group 28 . Recent health economic studies have demonstrated that patients spent less time in hospital (emergency room visits, ward stays, intensive care unit use) after being treated with VNS 29, 30 . Finally, there is an urgent need to readjust quotas allocated to adult epilepsy centers because paediatric epilepsy centers are currently implanting almost twice as many VNS devices as adult epilepsy centers. Considering that approximately two thirds of patients elect to replace their batteries after approximately 7-10 years 31 , there is a risk that adult epilepsy centers may no longer be able to do new implants due to the need to replace the dying batteries of former paediatric patients transferred to adult centers for continuing care. Ideally, an expert panel should be convened by the Health Ministry to evaluate short term needs, establish projections and develop a comprehensive policy, not only VNS but also neurostimulation in general for the treatment of epilepsy, considering recent positive results with deep brain stimulation 32 and responsive neurostimulation 33 .
CONCLUSION
In summary, VNS as practiced at Notre-Dame hospital is an efficacious and safe treatment for refractory epilepsy. Quotas allotted to epilepsy centers in the province of Quebec and the rest of Canada should be lifted or increased to allow more patients to benefit from this therapeutic device.
